|Dr. Taylor H. Schreiber M.D., Ph.D.||Co-Founder, CEO & Director||744.45k||N/A||1980|
|Dr. Arundathy Nirmalini Pandite M.B.A., M.D.||Chief Medical Officer||638.44k||N/A||1959|
|Ms. Casi DeYoung||Chief Bus. Officer||523.48k||N/A||1971|
|Mr. Andrew R. Neill M.B.A.||Chief Financial Officer||N/A||N/A||1986|
|Conor Richardson||Sr. Director of Fin. & Investor Relations||N/A||N/A||N/A|
|Dr. Abhinav A. Shukla Ph.D.||Chief Technical Officer||N/A||N/A||1973|
|Ms. Erin Ator Thomson J.D.||Gen. Counsel, Corp. Sec. and Chief Ethics & Compliance Officer||N/A||N/A||1980|
|Dr. Thomas Lampkin Pharm.D.||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Fatima Rangwala M.D., Ph.D.||Sr. VP of Clinical Research||N/A||N/A||N/A|
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.’s ISS governance QualityScore as of 1 September 2022 is 7. The pillar scores are Audit: 7; Board: 5; Shareholder rights: 8; Compensation: 8.